



# BIOFIL CHEMICALS & PHARMACEUTICALS LTD.

Regd. Office : 11/12, Sector-E, Sanwer Road, Industrial Area, Indore - 452 015. Fax : 0731-2723017  
Tel. : 0731-2723016, 4066216 E-mail : biofilchemicals@yahoo.com / bcplcompliance@gmail.com  
Factory : Plot No. 8, Sector - IV, Kheda Industrial Area, Pithampur Distt. Dhar (M.P.)

Admn. Office : B-12/B, Industrial Estate, Pologround, Indore - 452 015 (M.P.)  
Tel. : 0731-2426700, 2426718, 2524003, Fax : 0731-2426726 • CIN : L24233MP1985PLC002709

Date: 13/02/2019

To,  
The Company Secretary,  
Corporate Compliance Department  
The National Stock Exchange of India Limited  
Bandra Kurla Complex, Mumbai

To,  
The Company Secretary  
Corporate Compliance Department  
Bombay Stock Exchange Limited  
Dalal Street, P.J. Tower, Mumbai

Sub: - Submission of Un-Audited Financial Results for the quarter as well as nine months ended 31<sup>st</sup> December, 2018 along with Limited Review Report as per Regulation 33 of the SEBI (Listing Obligations & Disclosure Requirements) Regulation, 2015.

Ref: BSE Security Code: 524396; NSE Symbol: BIOFILCHEM; ISIN: INE829A01014

Dear Sir/Madam

Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulation 2015, we are enclosing Un-audited Financial Results along with Limited Review Report for the quarter as well as nine months ended 31<sup>st</sup> December, 2018 duly approved by the Board of the Directors of the Company in their meeting held today i.e. on 13<sup>th</sup> Day of February, 2019.

Further, copy of Un-Audited Financial Statements and Limited Review Report shall also be submitted in XBRL mode (Excel Template provided by Exchange) within 24 hours from the conclusion of Board Meeting.


The aforesaid results will be published in one Hindi (vernacular) and widely circulated English Newspaper. These results shall also be uploaded on the website of the Company i.e. [www.biofilgroup.net](http://www.biofilgroup.net) and on the website of the Stock Exchanges at [www.bseindia.com](http://www.bseindia.com) and [www.nseindia.com](http://www.nseindia.com).

You are requested to take on record the above said financial results for your reference and record.

Thanking you,

Yours Faithfully

For Biofil Chemicals and Pharmaceuticals Limited

  
Ramesh Shah  
Managing Director  
DIN :- 00028819





**MAHESHWARI & GUPTA**  
**CHARTERED ACCOUNTANTS**

**Limited Review Report**

The Board of Directors,  
M/S Biofil Chemicals And Pharmaceuticals Limited  
11/12, Sector E Sanwer Road  
Industrial Area  
Indore 452015 -M.P.

We have reviewed the accompanying statement of unaudited financial results (the "Statement") of Biofil Chemicals and Pharmaceuticals Limited ("the Company") for the quarter and nine months ended 31<sup>st</sup> December 2018 attached herewith, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. This statement is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, "Review of interim Financial information performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards i.e. Ind AS prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder, SEBI Circular CIF/CFD/CMD/15/2015 dated 30<sup>th</sup> November 2015, and CIR/CFD/FAC/62/2016 dated 5<sup>th</sup> July 2016, and other recognized accounting practices and policies has not disclosed the information required to be disclosed in accordance with the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

For MAHESHWARI & GUPTA  
Chartered Accountants

CA. SUNIL MAHESHWARI  
Partner  
M No. 403346

Place : INDORE  
Date : 13/02/2019

# Biofil Chemicals and Pharmaceuticals Limited

Registered Office: 11/12, Sector-'E' Sanwer Road, Industrial Area, Indore (M.P.)-452015

CIN: L24233MP1985PLC002709

Email : bcplcompliance@gmail.com

Tel : 0731-2723016


## UN- AUDITED FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTH ENDED 31ST DECEMBER, 2018

(Amount in Lakhs except EPS)

|       | Particulars   | Quarter Ended               |                                       |  | Nine Month Ended   |   | Audited for the year ended March 31 2018 |
|-------|---|-----------------------------|---------------------------------------|--|--|---|--|
|       |   | 3 months ended (31/12/2018) | Preceding 3 months ended (30/09/2018) | Corresponding 3 months ended in the previous year (31/12/2017) | Year to date figures for current period ended (31/12/2018) | Year to date figures for the previous year ended (31/12/2017) |  |
|       |   | Un- audited                 | Un- audited                           | Un- audited  | Un- audited  | Un-audited  | Audited                                  |
| I     | Revenue from Operation  | 1429.40                     | 213.60                                | 91.11  | 2065.41  | 880.82  | 1236.00                                  |
| II    | Other Income  | 2.02                        | 2.00                                  | 3.69   | 5.68   | 4.70  | 10.07                                    |
| III   | <b>Total Revenue (I + II)</b>   | <b>1431.42</b>              | <b>215.61</b>                         | <b>94.80</b>   | <b>2071.09</b>   | <b>885.52</b>   | <b>1246.07</b>                           |
| IV    | <b>Expenses</b>   |                             |                                       |  |  |   |  |
|       | (a) Cost of materials consumed  | 31.13                       | 20.52                                 | 13.15  | 63.94  | 38.88   | 77.75                                    |
|       | (b) Purchases of stock-in-trade   | 557.37                      | 864.49                                | 14.18  | 1835.00  | 712.98  | 991.06                                   |
|       | (c) Changes in inventories of finished goods, work-in-progress and stock-in-trade | 758.01                      | -738.74                               | 0.50   | -40.13   | -5.90   | -91.70                                   |
|       | (d) Employee benefits expense   | 20.91                       | 20.19                                 | 18.01  | 62.29  | 41.04   | 72.93                                    |
|       | (e) Finance Cost  | 3.88                        | 3.92                                  | 3.77   | 11.67  | 11.38   | 15.06                                    |
|       | (f) Depreciation and Amortisation Expense   | 7.44                        | 7.11                                  | 7.11   | 22.04  | 21.33   | 29.63                                    |
|       | (g) Other expenses  | 23.37                       | 27.64                                 | 15.73  | 70.08  | 26.50   | 92.53                                    |
|       | <b>Total expenses (IV)</b>  | <b>1402.10</b>              | <b>205.13</b>                         | <b>72.44</b>   | <b>2024.90</b>   | <b>846.20</b>   | <b>1187.25</b>                           |
| V     | <b>Profit (Loss) before exceptional items and tax (III-IV)</b>                    | <b>29.31</b>                | <b>10.48</b>                          | <b>22.35</b>   | <b>46.20</b>   | <b>39.32</b>  | <b>58.82</b>                             |
| VI    | <b>Exceptional Items</b>  | <b>0.00</b>                 | <b>0.00</b>                           | <b>0.00</b>  | <b>0.00</b>  | <b>0.00</b>   | <b>0.00</b>                              |
| VII   | <b>Profit (Loss) before tax (V - VI)</b>  | <b>29.31</b>                | <b>10.48</b>                          | <b>22.35</b>   | <b>46.20</b>   | <b>39.32</b>  | <b>58.82</b>                             |
| VIII  | <b>Tax expense:</b>   |                             |                                       |  |  |   |  |
|       | (1) Current tax   | 0.00                        | 0.00                                  | 0.00   | 0.00   | 0.00  | 11.75                                    |
|       | (2) Deferred tax  | 0.00                        | 0.00                                  | 0.00   | 0.00   | 0.00  | 0.00                                     |
| IX    | <b>Profit (Loss) for the period from continuing operation (VII-VIII)</b>          | <b>29.31</b>                | <b>10.48</b>                          | <b>22.35</b>   | <b>46.20</b>   | <b>39.32</b>  | <b>47.07</b>                             |
| X     | <b>Profit (Loss) for the period for dis-continued operation</b>                   | <b>0.00</b>                 | <b>0.00</b>                           | <b>0.00</b>  | <b>0.00</b>  | <b>0.00</b>   | <b>0.00</b>                              |
| XI    | <b>Tax expenses of discontinued operation</b>                                     | <b>0.00</b>                 | <b>0.00</b>                           | <b>0.00</b>  | <b>0.00</b>  | <b>0.00</b>   | <b>0.00</b>                              |
| XII   | <b>Profit/(Loss) for the period for dis-continued operation after tax (X-XI)</b>  | <b>0.00</b>                 | <b>0.00</b>                           | <b>0.00</b>  | <b>0.00</b>  | <b>0.00</b>   | <b>0.00</b>                              |
| XIII  | <b>Profit (Loss) for the period (IX+XII)</b>                                      | <b>29.31</b>                | <b>10.48</b>                          | <b>22.35</b>   | <b>46.20</b>   | <b>39.32</b>  | <b>47.07</b>                             |
| XIV   | <b>Other Comprehensive Income</b>   |                             |                                       |  |  |   |  |
|       | A) (I) Items that will not be reclassified to Profit or Loss                      | 0.00                        | 0.00                                  | 0.00   | 0.00   | 0.00  | 0.00                                     |
|       | (II) Income Tax relating to items that will not be reclassified to Profit or Loss |                             |                                       |  |  |   |  |
|       | B) (i) Items that will be reclassified to Profit or Loss                          | 0.00                        | 0.00                                  | 0.00   | 0.00   | 0.00  | 0.00                                     |
|       | (II) Income Tax relating to items that will be reclassified to Profit or Loss     |                             |                                       |  |  |   |  |
|       | <b>Other Comprehensive Income (net of tax) (A+B)</b>                              | <b>0.00</b>                 | <b>0.00</b>                           | <b>0.00</b>  | <b>0.00</b>  | <b>0.00</b>   | <b>0.00</b>                              |
| XV    | <b>Total Comprehensive Income for the period (XIII + XIV)</b>                     | <b>29.31</b>                | <b>10.48</b>                          | <b>22.35</b>   | <b>46.20</b>   | <b>39.32</b>  | <b>47.07</b>                             |
| XVI   | <b>Paid-Up equity share capital (face value of Rs 10/- each)</b>                  | <b>1627.38</b>              | <b>1627.38</b>                        | <b>1627.38</b>   | <b>1627.38</b>   | <b>1627.38</b>  | <b>1627.38</b>                           |
| XVII  | <b>Other Equity excluding Revaluation Reserve as per balance Sheet</b>            |                             |                                       |  |  |   | <b>-686.86</b>                           |
| XVIII | <b>Earnings per equity shares: (not annualised)</b>                               |                             |                                       |  |  |   |  |
|       | (1) Basic (Rs)  | 0.18                        | 0.06                                  | 0.14   | 0.28   | 0.24  | 0.29                                     |
|       | (2) Diluted (Rs)  | 0.18                        | 0.06                                  | 0.14   | 0.28   | 0.24  | 0.29                                     |

1. The standalone unaudited financial results of Biofil Chemicals & Pharmaceuticals Ltd, ("the company") for the quarter and nine months ended December 31, 2018 were reviewed by the Audit committee and approved by the Board of Directors at their meeting held on February 13, 2019.

2. The Limited Review of the financial Results of the Quarter and nine months ended 31st December 2018 pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosures Requirements) Regulations 2015, has been carried out by the Statutory Auditors.



3. The Company has reported segment wise information as per Accounting Standard (AS-17). The Operations of the company are conducted within India, there is no separate reportable geographical segment and the company reported the following business segments

- I. Pharma Product
- II. Chemicals Division
- III. Plastic Division

4. This statement has been prepared in accordance with the Companies (Indian Accounting Standards) Rules, 2015 (Ind AS) prescribed under section 133 of the Companies Act, 2013 and other recognised accounting practices and policies to the extent applicable.

5. The figures of the previous period / year have been re-stated/ re-grouped / re-arranged/ reclassified and / or recasted wherever found necessary.


6. The aforesaid audited financial Results will be uploaded on the Company's website [www.biofilgroup.net](http://www.biofilgroup.net) and will also be available on the websites of the Stock exchanges i.e. [www.bseindia.com](http://www.bseindia.com) and [www.nseindia.com](http://www.nseindia.com) for the benefit of shareholders and investors

7. Post applicability of Goods & Service Tax (GST) with effect from July 01, 2017 Revenue from Operations are disclosed exclusive of GST. Consequently Revenue from Operations for the nine month ended December 31, 2018 is not comparable with corresponding period of Previous year

Date : 13-02-2019

Place : Indore

For Biofil Chemicals and Pharmaceuticals Limited



RAMESH SHAH  
MANAGING DIRECTOR  
( DIN : 00028819)

# Biofil Chemicals and Pharmaceuticals Limited

Registered Office: 11/12, Sector-'E' Sanwer Road, Industrial Area, Indore (M.P.)-452015

CIN L24233MP1985PLC002709

Email : bcplcompliance@gmail.com

Tel : 0731-2723016

Segment wise Revenue, Results and Capital Employed for quarter and nine months ended 31st Dec 2018


( Amount in Lakhs)

| S.No. | Particulars  | Quarter Ended            |                          |                          | Nine Month Ended         |                          |                       |
|-------|--|--------------------------|--------------------------|--------------------------|--------------------------|--------------------------|-----------------------|
|       |  | Dec 31 ,<br>2018         | Sept 30 ,<br>2018        | Dec 31 ,<br>2017         | Dec 31 ,<br>2018         | Dec 31 ,<br>2017         | 31 March<br>2018      |
|       |  | Un-audited<br>31.12.2018 | Un-audited<br>30-09-2018 | Un-audited<br>31.12.2017 | Un-audited<br>31.12.2018 | Un-audited<br>31.12.2017 | Audited<br>31.03.2018 |
| 1     | <b>Segment Revenue</b>   |                          |                          |                          |                          |                          |                       |
|       | Pharma Unit  | 1,379.95                 | 147.85                   | 36.58                    | 1,909.23                 | 752.10                   | 1,053.13              |
|       | Chemicals Division   | 49.45                    | 65.75                    | 54.53                    | 156.18                   | 125.88                   | 180.02                |
|       | Plastic Division   | 0.00                     | 0.00                     | 0.00                     | 2.84                     | 2.84                     | 2.84                  |
|       | Other  | 2.02                     | 2.00                     | 3.69                     | 5.68                     | 4.70                     | 10.07                 |
|       | <b>Gross Turnover</b>  | <b>1,431.42</b>          | <b>215.61</b>            | <b>94.80</b>             | <b>2,073.94</b>          | <b>885.52</b>            | <b>1,246.07</b>       |
| 2     | <b>Segment Results</b>   |                          |                          |                          |                          |                          |                       |
|       | Pharma Unit  | 18.19                    | 12.90                    | 8.30                     | 35.71                    | 25.53                    | 56.31                 |
|       | Chemicals Division   | 15.00                    | 5.20                     | 21.55                    | 26.89                    | 33.46                    | 26.91                 |
|       | Plastic Division   | 0.00                     | (3.88)                   | (3.75)                   | (4.95)                   | (8.41)                   | (4.01)                |
|       | Other  |                          |                          |                          | 0.00                     | 0.00                     | (8.41)                |
|       | <b>Total Segment Profit Before Tax</b>                             | <b>33.19</b>             | <b>14.23</b>             | <b>26.10</b>             | <b>57.66</b>             | <b>50.57</b>             | <b>70.79</b>          |
|       | Interest Income  |                          | 0.00                     |                          | 0.00                     | 0.00                     | 3.03                  |
|       | Interest Expenses  | 3.88                     | 3.75                     | 3.75                     | 11.46                    | 11.25                    | 15.00                 |
|       | Other Unallocable Income net off un allocable expenditure          |                          |                          |                          |                          |                          |                       |
|       | <b>Profit Before Tax</b>   | <b>29.31</b>             | <b>10.48</b>             | <b>22.35</b>             | <b>46.20</b>             | <b>39.32</b>             | <b>58.82</b>          |
|       | Provision for current tax  | 0.00                     | 0.00                     | 0.00                     | 0.00                     |                          | 11.30                 |
|       | Item Related Earlier Year  | 0.00                     | 0.00                     | 0.00                     | 0.00                     |                          | 0.45                  |
|       | <b>Profit After Tax</b>  | <b>29.31</b>             | <b>10.48</b>             | <b>22.35</b>             | <b>46.20</b>             | <b>39.32</b>             | <b>47.07</b>          |
| 3     | <b>Capital Employed</b>  |                          |                          |                          |                          |                          |                       |
|       | <b>Segment Assets (A)</b>  |                          |                          |                          |                          |                          |                       |
|       | Pharma Division  | 2,378.71                 | 1,601.67                 | 1,417.27                 | 2,378.71                 | 1,417.27                 | 1,485.86              |
|       | Chemicals Division   | 914.37                   | 959.84                   | 854.12                   | 914.37                   | 854.12                   | 866.71                |
|       | Plastic Division   | 60.45                    | 120.70                   | 67.88                    | 60.45                    | 67.88                    | 62.89                 |
|       | Other  |                          |                          |                          |                          |                          |                       |
|       | <b>Total (A)</b>   | <b>3,353.52</b>          | <b>2,682.21</b>          | <b>2,339.26</b>          | <b>3,353.52</b>          | <b>2,339.26</b>          | <b>2,415.46</b>       |
|       | <b>Segment Liabilities (B)</b>                                     |                          |                          |                          |                          |                          |                       |
|       | Pharma Division  | 1,815.79                 | 1,079.07                 | 874.91                   | 1,815.79                 | 874.91                   | 898.26                |
|       | Chemicals Division   | 35.65                    | 64.29                    | 40.47                    | 35.65                    | 40.47                    | 41.52                 |
|       | Plastic Division   | 169.52                   | 166.03                   | 152.24                   | 169.52                   | 152.24                   | 158.96                |
|       | Other  |                          |                          |                          |                          | 0.00                     |                       |
|       | <b>Total (B)</b>   | <b>2,020.96</b>          | <b>1,309.39</b>          | <b>1,067.61</b>          | <b>2,020.96</b>          | <b>1,067.61</b>          | <b>1,098.74</b>       |
|       | <b>Total Capital Employed (Segment Assets-Segment Liabilities)</b> |                          |                          |                          |                          |                          |                       |
|       | Pharma Division  | 562.92                   | 522.60                   | 542.36                   | 562.92                   | 542.36                   | 587.60                |
|       | Chemicals Division   | 878.72                   | 895.56                   | 813.65                   | 878.72                   | 813.65                   | 825.19                |
|       | Plastic Division   | (109.07)                 | (45.33)                  | (84.36)                  | (109.07)                 | (84.36)                  | (96.07)               |
|       | Other  | 0.00                     | 0.00                     | 0.00                     | 0.00                     | 0.00                     | 0.00                  |
|       | <b>Total Capital Employed (Segment Assets-Segment Liabilities)</b> | <b>1,332.57</b>          | <b>1,372.83</b>          | <b>1,271.65</b>          | <b>1,332.57</b>          | <b>1,271.65</b>          | <b>1,316.73</b>       |

DATE : 13-02-2019

PLACE : INDORE

BIOFIL CHEMICALS AND PHARMACEUTICALS LIMITED



RAMESH SHAH  
MANAGING DIRECTOR  
DIN: 00028819

